menu-close-icon
Your using an unsupported browser. Please update to a modern browser for a better experience.
Skip to content
Clario Clario
  • Solutions
    • Study Endpoints
        • Cardiac safety and efficacy endpoint solutions for all phases, anywhere in the world.

        • Collect continuous ECG data in site-based or hybrid trials with our flexible solutions and patient-friendly devices.

        • Collect and centrally analyze accurate, consistent, quality blood pressure data from site-based to hybrid trials.

        • Monitor every heartbeat with precision to assess safety and efficacy throughout your site-based or hybrid clinical trial.

        • Fulfill your ICH E14 requirement early, minimize risk and potentially reduce costs throughout your trial.

        • Leverage our key opinion leaders to understand the complex regulatory landscape while minimizing risk with confidence.

        • Make your clinical trials easier, faster, more engaging and accessible to all.

        • Deliver reliable, scalable, and regulatory-ready eCOA for global Central Nervous System (CNS) trials.

        • Accelerate your clinical trial setup with Clario’s pre-validated and configured eCOA assessments.

        • Expert guidance for capturing high-quality, regulatory compliant data from the right participants, at the right time, in clinic or at home.

        • Improve data accuracy and reduce variability in scoring with Clario’s training solutions.

        • Your trusted partner for the richest eCOA endpoint data in your clinical trial.

        • Monitor Suicide Ideation and Behavior (SIB) in clinical trials effectively with Clario’s suicide assessment tool, eC-SSRS.

        • Enjoy flexible, fast and confidential site assessments at home.

        • Enhance your ePRO data with photo and audio capture.

        • Accelerate drug development and reduce risk with Clario’s comprehensive medical imaging core lab services.

        • The Clario team includes medical imaging experts and globally recognized key opinion leaders (KOLs) representing multiple disciplines.

        • Clario’s Image Redact AI automatically redacts sensitive patient identifiers from videos, photos and PDFs.

        • Secure accurate results, streamline your processes, and meet your unique needs with our imaging platform.

        • Leverage our full range of medical imaging and diagnostic imaging modalities, including CT Scans, Endoscopy, MRIs, and more.

        • Securely collect, store, and share de-identified images for compliance with 21 CFR Part 11 and EU GDPR standards.

        • Clario's complete solution for measuring objective digital endpoints of mobility with wearable sensor technology.

        • The Opal V2R® is a research grade wearable sensor that delivers meaningful outcomes and richer insights.

        • Explore more than 750 scientific publications that reflect the technical and clinical applications of Clario’s Opal® System.

        • Everything you need for high quality, low variability pulmonary function data and high patient compliance for clinical trials.

        • Improve your data quality, monitor for proper technique and leverage the power of AI to make interpretation of spirometry tests easier, faster and more consistent.

        • Centralized, on-site pulmonary function testing for clinical trials.

        • Remote spirometry testing for respiratory clinical trials.

        • Assess cough frequency, cough severity and other lung sounds such as crackles or rhonchi for clinical trials.

        • Assess the capacity of the lungs for effective gas transfer.

        • Advanced, cloud-native technologies and clinical trial software to screen, clean, QC and assess complicated data.

        • Collect, centralize and manage participant screening and eligibility data with customized workflows.

        • Boost stakeholder insights with business intelligence (BI) tools, analytics for endpoint and safety risks, and data exchange solutions.

        • Securely collect, store and share compliant images in the cloud to keep clinical trial sponsors and labs informed.

    • Segments
    • Study Phases
    • Technology
  • Therapeutic Areas
    • Cardiovascular & Metabolic Icon RGBCardiovascular & Metabolic
    • Dermatology Icon RGBDermatology
    • Type 2 Diabetes and Obesity iconDiabetes and Obesity
    • Gastroenterology Icon RGBGastroenterology
    • Hepatology Icon RGBHepatology
    • Infectious Disease Icon RGBInfectious Diseases
    • Muskoskeletal Icon RGBMusculoskeletal
    • Neuroscience Icon RGBNeuroscience
      • Neuroscience Indications
    • Oncology Icon RGBOncology
    • Ophthalmology Icon RGBOphthalmology
    • Respiratory Solutions IconRespiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Careers
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Newsroom
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
  • Solutions
    • Study Endpoints
      • Cardiac Solutions
        • Cardiac Solutions
        • Arrhythmia Analysis
        • Blood Pressure Services
        • ECG — On-site to DCT and Phase I-IV
        • Phase I/TQT Cardiac Assessment
        • Regulatory Consultation and Statistical Analysis Expertise
      • Clinical Adjudication
      • eCOA
        • eCOA Clinical Trials
        • eCOA Neuroscience
        • eCOA Rapid Start
        • eCOA Science Services
        • eCOA Rater and Participant Training
        • eCOA Rescue Studies
        • Suicidal Ideation
        • eCOA Live
        • eCOA Multimedia
      • Medical Imaging
        • Medical Imaging
        • Image Redact AI
        • Imaging Platform
        • Medical Imaging Science Team
        • Modalities
        • SMART Submit
      • Precision Motion
        • Precision Motion for Clinical Trials
        • Precision Motion for Research
        • Precision Motion: Scientific Publications
      • Respiratory Solutions
        • Respiratory Solutions
        • Respiratory Solutions for Healthcare Providers
        • Site-Based Spirometry
        • Virtual Home Spirometry
        • Cough and Lung Sounds
        • Diffusing Capacity (DLCO)
      • Trial Enablement
        • Trial Enablement
        • Eligibility Solution
        • Reporting & Analytics
        • Source Document Manager
    • Segments
      • Biotechs
      • CROs
      • Pharma
    • Study Phases
      • Phase I
      • Phase II/III
    • Technology
      • Artificial Intelligence (AI)
      • Hybrid Trials
  • Therapeutic Areas
    • Cardiovascular & Metabolic
    • Dermatology
    • Diabetes and Obesity
    • Gastroenterology
    • Hepatology
    • Infectious Diseases
    • Musculoskeletal
    • Neuroscience
      • Dementias
      • Headache Disorders
      • Movement Disorders
      • Multiple Sclerosis
      • Pain Disorders
      • Psychiatric Disorders
    • Oncology
    • Ophthalmology
    • Respiratory
  • Resources
    • Blog Articles
    • Case Studies
    • Downloads
    • Events
    • External Publications
    • Webinars
  • About
    • The Clario Story
    • Corporate & Social Responsibility
    • Information Security
    • Leadership
    • Legal & Privacy
    • Scientific Expertise
    • Strategic Partnerships
    • Values and Culture
  • Support
    • Customer Support
    • In-Country Customer Support
  • Careers
    • Life at Clario
  • Newsroom
  • Login
  • Contact sales
    • Log in
    • Contact sales
  1. Home Resources Blog Articles Researcher spotlight: Nathan Meier, Ph.D.

Researcher spotlight: Nathan Meier, Ph.D.

Precision Motion

nathan meier headshot
nathan meier headshot

Nathan Meier, Ph.D.

Associate Professor, Concordia University Irvine

Opal® V2R Technology has been used by thousands of researchers worldwide and together, these researchers have published more than 800 peer reviewed papers, greatly contributing to available body of evidence in human movement.

APDM, now owned by Clario, has delivered deep scientific expertise and broad endpoint technologies to help transform lives around the world for more than 50 years. Our endpoint data solutions have been deployed over 26,000 times to support clinical trials in more than 100 countries. Our global team of science, technology, and operational experts have supported over 60% of all FDA drug approvals since 2012.

For more information, visit our Wearable Biosensors for Research page. 

Q:

Would you please introduce yourself, your academic background and your research interests?

A:

My name is Nathan Meier. I have a Ph.D. in Kinesiology from Iowa State University. I studied physical activity and epidemiology as well as exercise psychology in my graduate work. I’ve come to focus on an area of lifestyle medicine as my main interest. In this regard I care deeply about the value of daily decisions and their contribution to human health and flourishing, risk factors for disease, disease outcomes and mortality.  

My research interests have developed at Concordia University Irvine, where I’m an associate professor, mentoring many wonderful students, but especially working to provide opportunities for meaningful interactions with patient populations to build tangible skills and learn the research process from IRB to peer-review manuscript submission. The main focus has been engaging with our Southern California Parkinson’s Disease community. With many years and nearly 100 undergraduate research assistants we have started the Lifestyle and Parkinson’s Disease Longitudinal Study (www.cui.edu/lpls). From this project we have a multiyear observational dataset from which to ask some very useful research questions.

Q:

Do you have a personal story that led to your interest in human movement/neurodegenerative disease research?

What continues to drive your ambitions as a scientist?

A:

My uncle PJ was diagnosed with early onset Parkinson’s Disease and recently died. My interactions with him and the family’s work to provide him care was very impactful. Subsequently, a particular student, Oliver, and I developed a partnership with a local Rock Steady Boxing group and we began the process of developing LPLS.

My ambitions as a scientist come from my desire to serve God with my work and love people by working to provide translational research findings to benefit those who suffer from PD.  Ultimately, I hope to honor God with my life and hope that the training of students and fostering their talents and passions will provide health and healing for patients and people in general.

Q:

How has Clario’s APDM Opal V2R® System been most useful in your research endeavors?

A:

My interactions with Clario as a company has been very positive, with great relationships and support for my lab’s research. It has also provided my department with great interdisciplinary research opportunities, specifically with my work as an epidemiologist and my colleague’s work in biomechanics. Together, we collaborate to explore kinematic data in a large sample of people with PD. Without my colleague’s expertise, we would likely continue to only use field tests of physical function and not very high quality detailed kinematics. The level of specificity that these sensors and software provide allows us to detect much smaller changes in the participants.

Q:

What research projects or questions are you currently working on?

A:

Our LPLS dataset allows us to explore the effects of modifiable risk factors on disease progression. The integration of Clario’s kinematic data allows us to explore the changes in biomechanical variables over time. I am validating a new 3D video capture system for assessing PD motor symptoms compared to expert reviewers to help solve issues of interrater variation in assessments and provide access to detailed information on motor symptoms in more remote locations where neurologists are limited. The lab is also collaborating with a local non-profit to quantify the benefits of participating in dance classes on neurological conditions. We have also been able to develop collaboration with a biochemistry lab to explore our data alongside gastrointestinal health and dysfunction.

Q:

Where do you see the use of wearable IMU’s in human movement research going in the next 5 years?

A:

The versatility of the wearable technology is wonderful in exploring a wide range of issues affecting our aging population. We hope to integrate the sensors into our undergraduate classes and train our students to use the latest technology in kinesiology, biomechanics, medicine and research. This technology and data will only increase exponentially into the future in Kinesiology and many other fields.

Q:

What advice would you give a researcher just starting out in your field? 

A:

I have found that starting with core principals, your own personal motivation and deepest values, is key to finding a fit in research. I am also blessed by the relationships that I have formed through serving my students, my university and my community. I find that the more I am able to give of myself, the more opportunities God provides for meaningful work in research.

Q:

Fill in the blank: When I’m not working on a research project, you can find me…

A:

Spending time with my wife, cooking, doing house projects and hiking. I am also keeping up with judo training and weight lifting to stay active and hope to maintain my body’s physical function throughout my whole lifespan, as many years as I am blessed to enjoy.

Nathan’s latest publication:

Reliability and validity of a full-body function Get-Up test in older adults – PMC

Learn more about Opal wearable sensors or be featured in an upcoming researcher spotlight

Contact Clario Precision Motion
Back to articles
Share
Twitter Facebook LinkedIn

Latest articles

See all articles
Article

Six key takeaways from the FDA’s 10th Annual COA in Cancer Clinical Trials Workshop

6 key highlights and recurring themes from the workshop

Read
Article

Researcher spotlight: Deborah Jehu, Ph.D.

Precision Motion

Read
Article

Researcher spotlight: Nora Fritz, Ph.D., PT, DPT, NCS

Precision Motion

Read
Clario logo
    • Solutions
    • Therapeutic Areas
    • About
    • Resources
    • Careers
    • Newsroom
  • Get in touch

    • Contact
    • Support
    • Customer portal

Follow us

Twitter LinkedIn Glassdoor
×

Contact sales

If you are looking for a partner to help you generate the richest clinical evidence with the right clinical trial technology, please fill in the form below.


Not what you're looking for?

Please visit our Contact Page for customer support, office locations, or media contacts.

  • © 2025 Clario

    • Legal and Privacy Terms
    • Information Security
    • Cookie Policy
    • Impressum